It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Despite decades of genetic studies on late-onset Alzheimer’s disease, the underlying molecular mechanisms remain unclear. To better comprehend its complex etiology, we use an integrative approach to build robust predictive (causal) network models using two large human multi-omics datasets. We delineate bulk-tissue gene expression into single cell-type gene expression and integrate clinical and pathologic traits, single nucleotide variation, and deconvoluted gene expression for the construction of cell type-specific predictive network models. Here, we focus on neuron-specific network models and prioritize 19 predicted key drivers modulating Alzheimer’s pathology, which we then validate by knockdown in human induced pluripotent stem cell-derived neurons. We find that neuronal knockdown of 10 of the 19 targets significantly modulates levels of amyloid-beta and/or phosphorylated tau peptides, most notably JMJD6. We also confirm our network structure by RNA sequencing in the neurons following knockdown of each of the 10 targets, which additionally predicts that they are upstream regulators of REST and VGF. Our work thus identifies robust neuronal key drivers of the Alzheimer’s-associated network state which may represent therapeutic targets with relevance to both amyloid and tau pathology in Alzheimer’s disease.
A network analysis on deconvoluted bulk transcriptomic data from human Alzheimer’s disease cohorts identifies several potential key disease drivers, including JMJD6.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Brigham and Women’s Hospital and Harvard Medical School, Ann Romney Center for Neurologic Diseases, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); University of Pennsylvania Perelman School of Medicine, Neuroscience Graduate Group, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
2 University of Arizona, The Center for Innovation in Brain Sciences, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
3 Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK (GRID:grid.48004.38) (ISNI:0000 0004 1936 9764); Malawi–Liverpool—Wellcome Trust Clinical Research Programme, Blantyre, Malawi (GRID:grid.419393.5) (ISNI:0000 0004 8340 2442)
4 University of Arizona, The Center for Innovation in Brain Sciences, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X); University of Arizona, Arizona Research Labs, Genetics Core, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
5 Brigham and Women’s Hospital and Harvard Medical School, Ann Romney Center for Neurologic Diseases, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
6 Rush University Medical Center, Rush Alzheimer’s Disease Center, Chicago, USA (GRID:grid.240684.c) (ISNI:0000 0001 0705 3621)
7 Mayo Clinic Florida, Department of Neuroscience, Jacksonville, USA (GRID:grid.417467.7) (ISNI:0000 0004 0443 9942); Mayo Clinic Florida, Department of Neurology, Jacksonville, USA (GRID:grid.417467.7) (ISNI:0000 0004 0443 9942)
8 Brigham and Women’s Hospital and Harvard Medical School, Ann Romney Center for Neurologic Diseases, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Harvard University, Harvard Stem Cell Institute, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
9 University of Arizona, The Center for Innovation in Brain Sciences, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X); University of Arizona, Department of Neurology, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X); INTelico Therapeutics LLC, Tucson, USA (GRID:grid.134563.6); PATH Biotech LLC, Tucson, USA (GRID:grid.134563.6)